Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655130 add-on proof-of-concept study in ulcerative colitis during TNF inhibitor therapy
2016-004572-21Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of spesolimab in autoimmune colitis, sponsored by Boehringer Ingelheim. Primary endpoint: Mucosal healing. Started Mar 2017; status: terminated.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-004572-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004572-21.